What went well
  • Obefazimod delivered a transformational clinical readout just after the period end: on July 22, 2025 Abivax announced positive topline results from both ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week Phase 3 induction trials in moderately to severely active ulcerative colitis, with the 50 mg once-daily dose meeting the FDA primary endpoint of Week 8 clinical remission in both trials (placebo-adjusted 19.3%, p<0.0001 in ABTECT-1; 13.4%, p=0.0001 in ABTECT-2) and hitting all key secondary endpoints.
  • The ABTECT program enrolled 1,275 patients across more than 600 sites in 36 countries - one of the largest Phase 3 ulcerative colitis programs ever conducted - and included the largest population of prior-JAK-inhibitor-inadequate-responders studied to date, with obefazimod generally well tolerated and no new safety signals.
  • The readout de-risked the balance sheet: on July 28, 2025 Abivax closed a $747.5 million (approximately EUR 637.5 million gross / EUR 597.2 million net) underwritten U.S. public offering of ADSs, dramatically extending its cash runway.
  • The company deleveraged, with Heights Capital Management converting the entirety of its EUR 21.9 million convertible notes into equity in July/August 2025 (leaving no Heights debt), and Kreos Capital and Claret exercising/converting portions of their instruments into shares.
  • Sales & marketing costs fell to EUR 1.5 million (from EUR 4.2 million) and G&A costs declined to EUR 16.3 million (from EUR 17.9 million), reflecting cost discipline and the absence of prior-year one-time re-branding spend.
What went wrong
  • As a pre-revenue clinical-stage company, losses widened: the H1 2025 operating loss increased by EUR 13.7 million to EUR 93.7 million and the net loss increased by EUR 19.2 million to EUR 100.8 million versus H1 2024.
  • R&D expense rose EUR 13.2 million to EUR 77.9 million, driven by progression of the Crohn's disease Phase 2b program (+EUR 6.5 million) and expansion of R&D headcount and new equity awards (+EUR 5.7 million).
  • Operating income fell EUR 4.7 million to EUR 2.1 million (predominantly research tax credit and subsidies), and the net financial loss widened to EUR 7.1 million on EUR 6.9 million of interest expense and EUR 2.3 million of FX losses.
  • Pre-financing liquidity was thin: cash and cash equivalents fell to EUR 60.9 million at June 30, 2025 (from EUR 144.2 million at year-end 2024) and net financial position turned negative (EUR -20.2 million) with negative shareholders' equity of EUR -48.3 million before the July capital raise.
  • The equity raise and convertible-note conversions were dilutive to existing shareholders.

Guidance Changes

MetricPeriodCurrent guidance
Cash runwayas of H1 2025 reportPro forma for the July 2025 offering and note conversions, funded into the fourth quarter of 2027
ABTECT Phase 3 maintenance toplineupcomingExpected Q2 2026
NDA submission (obefazimod in UC)upcomingPlanned second half of 2026, pending successful maintenance results

Performance Breakdown

MetricYoYNote
Total operating income EUR 2.1M (H1'24: EUR 6.8M) Predominantly French research tax credit and subsidies; decreased EUR 4.7M year over year.
R&D costs EUR 77.9M (+EUR 13.2M) Crohn's disease Phase 2b progression and R&D headcount/equity-award expansion; UC program spend roughly stable.
Operating loss EUR 93.7M (+EUR 13.7M) Higher operating expenses partly offset by lower S&M and G&A.
Net loss EUR 100.8M (+EUR 19.2M) Wider operating loss plus a EUR 7.1M net financial loss.
Cash and cash equivalents EUR 60.9M at Jun 30, 2025 Down from EUR 144.2M at year-end 2024 on EUR 66.6M operating use and EUR 16.6M debt service - before the July 2025 EUR 637.5M gross raise.

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
Obefazimod / ABTECT Phase 3 UCInduction trials fully enrolledPositive 8-week induction topline (July 2025); 678 of 1,275 induction responders enrolled into the ongoing 44-week maintenance trial; NDA targeted for 2H 2026.—
Balance-sheet transformationThin cash, structured debt outstanding$747.5M July 2025 offering plus conversion of Heights notes and Kreos/Claret instruments materially strengthened liquidity and reduced debt.—

More on Abivax S.A.

Company

Abivax S.A. overview
Facet

Financials

See how VectorShift works for your firm

Request Demo